0001512922
false
0001512922
2023-06-29
2023-06-29
0001512922
us-gaap:CommonStockMember
2023-06-29
2023-06-29
0001512922
PETV:WarrantsMember
2023-06-29
2023-06-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
June
29, 2023
Date
of Report (Date of earliest event reported)
PETVIVO
HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
Nevada |
|
000-40715 |
|
99-0363559 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
5251
Edina Industrial Blvd.
Edina,
Minnesota |
|
55349 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(952)
405-6216
Registrant’s
telephone number, including area code
Check
the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock |
|
PETV |
|
The
Nasdaq Stock Market LLC |
Warrants |
|
PETVW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02 |
Results
of Operations and Financial Condition. |
On
June 29, 2023, PetVivo Holdings, Inc. (the “Company”) issued a press release regarding its financial results for its fiscal
year ended March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated
herein by reference.
The
information contained under this Item 2.02 in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not
be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that Section. Furthermore, the information contained under this Item 2.02 in this Current Report on Form 8-K, including
Exhibit 99.1, shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to
the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.
Item
9.01 |
Financial
Statements and Exhibits. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized
|
PETVIVO
HOLDINGS, INC. |
|
|
|
Date:
June 29, 2023 |
By: |
/s/
John Lai |
|
Name: |
John
Lai |
|
Title: |
Chief
Executive Officer |
Exhibit
99.1
PetVivo
Reports Fiscal 2023 Full Year Financial Results
Conference
call begins at 4:00 p.m. Central time today
EDINA,
MN (June 29, 2023) – PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization
of innovative medical therapeutics for animals, announces financial results for its fiscal year ended March 31, 2023 (“fiscal 2023”).
Key
highlights for our fiscal year ended March 31, 2023, were:
|
● |
Revenues
increased to $917,162 in fiscal 2023, compared to revenues of $115,586 for our fiscal year ended March 31, 2022 (“fiscal 2022”); |
|
|
|
|
●
|
Entered
into an exclusive distribution agreement (“Distribution Agreement”) with MWI Veterinary Supply, a leading distributor
of animal health products and a subsidiary of AmerisourceBergen (“MWI”) in June 2022. We recognized revenues from product
sales under the Distribution Agreement of $636,345 or 69% of total revenues for the year ended March 31, 2023; |
|
|
|
|
●
|
Increased
brand awareness and market awareness by participating in several key national trade shows and conferences, including having Dr. Joseph
Manning, DVM, the Company’s Senior Technical Veterinarian present on the use of Spryng™ at the American Association of
Equine Practitioners Annual Conference in November 2022; |
|
|
|
|
●
|
Reported
results on the first cohort of dogs in a clinical study, which examined the benefit and tolerability of an intra-articular injection
of Spryng™ into the stifle joint of dogs with suspected cruciate ligament damage or tear (similar to an anterior cruciate ligament
(“ACL”) tear in humans) in March 2023. The preliminary results demonstrated that Spryng™ may be a viable alternative
for medical management of dogs with an ACL injury; and |
|
|
|
|
●
|
Signed
a lease agreement for a new production and warehouse space in Edina, Minnesota in January 2023. We plan to have this facility operational
in the fourth quarter of our fiscal year ending March 31, 2024 (“fiscal 2024”).
|
Management
Commentary
John
Lai, CEO, commented, “I am pleased by our team’s performance. We executed well on our strategy of developing clinical data
on the efficacy of Spryng™, increased distribution through MWI, increased market awareness of Spryng™ to veterinarians and
delivered strong revenue growth in fiscal 2023.
We
are excited about the preliminary clinical results from the cruciate ligament study on canines and expect to receive the final clinical
results in Q2 of fiscal 2024. We expect to use this clinical data to expand the application of Spryng™ to treat canines and felines
who have cruciate ligament injuries.
We
are also taking several steps to position the Company for future success in fiscal 2024. We plan to add more sales and marketing personnel
to support our distribution relationship with MWI and veterinary clinics, add to our technical service teams, complete clinical studies
in equine, canine and feline companion animals, increase adoption of Spryng™ by key opinion leaders and increase marketing awareness
through trade shows and digital outreach.”
For
The Fiscal Year Ended March 31, 2023 Compared to The Fiscal Year Ended March 31, 2022
Total
Revenues. Revenues were $917,162 in fiscal 2023 compared to $115,586 for fiscal 2022. Revenues in fiscal 2023 consisted of sales
of our Spryng™ products to MWI of $636,345 and to veterinary clinics in the amount of $280,817. In fiscal 2022, our revenues of
$115,586 consisted of sales to veterinary clinics. The increase in our revenues in fiscal 2023 is due to sales to MWI pursuant to our
Distribution Agreement and increased sales to veterinary clinics.
Total
Cost of Sales. Cost of sales was $526,817 in fiscal 2023 compared to $201,154 for fiscal 2022. Cost of sales includes product
costs related to the sale of our Spryng™ products and labor and overhead costs. The increase in cost of sales in fiscal 2023 is
due to the increased sales to MWI pursuant to our Distribution Agreement and increased sales to veterinary clinics.
Operating
Expenses. Operating expenses increased to $9,123,797 in fiscal 2023 compared to $4,970,960 in fiscal 2022. Operating expenses
consisted of general and administrative (“G&A”), sales and marketing, and research and development expenses. The increase
is primarily due to increased G&A expenses and sales and marketing expenses related to the sale of our Spryng™ products.
General
and administrative expenses were $5,022,943 and $3,148,494 in fiscal 2023 and 2022, respectively. General and administrative expenses
include compensation and benefits, contracted services, consulting fees, stock compensation, and incremental public company costs.
Sales
and marketing expenses were $3,410,277 and $1,347,585 in fiscal 2023 and 2022, respectively. Sales and marketing expenses include compensation,
consulting, tradeshows, and stock compensation costs to support the launch of our Spryng™ products.
Research
and development (“R&D”) expenses were $690,577 and $474,881 in fiscal 2023 and 2022, respectively. The increase was related
to clinical studies and efforts to support the launch of Spryng™.
Operating
Loss. As a result of the foregoing, our operating loss was $8,733,452 and $5,056,528 in fiscal 2023 and 2022, respectively. The
increase was related to the costs to support the launch of Spryng™ and the incremental public company costs.
Other
Income. Other income was $15,844 in fiscal 2023 as compared to $41,533 in fiscal 2022. Other income in fiscal 2023 consisted
of net interest income of $15,844. Other income in fiscal 2022 consisted of the forgiveness of PPP Loan of $31,680 and net interest income
of $9,853.
Net
Loss. Our net loss in fiscal 2023 was $8,717,608 or ($0.85 per share) as compared to a net loss of $5,014,995 or ($0.57) per
share in fiscal 2022. The weighted average number of shares outstanding was 10,222,994 compared to 8,760,877 for fiscal 2023 and 2022,
respectively.
Balance
Sheet and Inventory
As
of March 31, 2023, our current assets were $1,423,980 including $475,314 in cash and cash equivalents. In comparison, our current liabilities
as of that date were $1,453,680 including $1,368,595 of accounts payable and accrued expenses. Our working capital deficit as of March
31, 2023 was $29,700.
At
March 31, 2023, the Company’s inventory had a carrying value of $370,283.
Going
Concern and Current Working Capital
The
Company’s audited financial statements for fiscal 2023, included in is Annual Report on Form 10-K filed with the SEC today, contained
a going concern opinion from its independent registered public accounting firm.
Subsequent
to its year-end, the Company raised net proceeds of approximately $2,094,000, after deducing offering expenses and commissions. The Company
believes its working capital is sufficient to fund operations through July 2023.
Conference
Call and Webcast
A
live webcast of the conference call and related earnings release materials can be accessed on the Company’s Investor Relations
website at: https://audience.mysequire.com/webinar-view?webinar_id=19521825-9284-4391-bfe3-8ed5b4ec0774
A
replay of the webcast will be available through the same link following the conference call. Participants can also access the call using
the dial-in details below:
Date:
Thursday, June 29, 2023
Time:
4:00 p.m. CT (5:00 pm ET)
Dial-in
number: 1-346-248-7799
Conference
ID: 92979093556
Passcode:
980888
About
PetVivo Holdings, Inc.
PetVivo
Holdings, Inc. (the “Company”) is an emerging biomedical device company currently focused on the manufacturing, commercialization,
and licensing of innovative medical devices and therapeutics for animals. The Company’s strategy is to leverage human therapies
for the treatment of dogs and horses in a capital and time-efficient way. A key component of this strategy is the accelerated timeline
to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
The
Company has a pipeline of additional products for the treatment of animals and people. A portfolio of nineteen patents protects the Company’s
biomaterials, products, production processes, and methods of use. The Company’s lead product is Spryng™, a veterinarian-administered,
intraarticular injection for the treatment of osteoarthritis in dogs and horses.
Cautionary
Note Regarding Forward-Looking Statements
This
press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act
of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without
limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,”
“will,” “expect,” “project,” “estimate,” “anticipate,” “plan,”
“believe,” “potential,” “should,” “continue” or the negative versions of those words
or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements
are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties
and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the
Company’s Annual Report on Form 10-K for the year ended March 31, 2023, and other periodic and current reports filed with the Securities
and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking
statements, whether as a result of new information, future events, or otherwise.
Disclosure
Information
The
Company uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information, and
for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor
Relations website, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations,
and webcasts.
Contact:
John
Lai, CEO
PetVivo
Holdings, Inc.
Email:
info1@petvivo.com
(952)
405-6216
PETVIVO
HOLDINGS, INC.
CONSOLIDATED
STATEMENTS OF OPERATIONS
| |
Year
Ended March 31,
| |
| |
2023 | | |
2022 | |
Revenues | |
$ | 917,162 | | |
$ | 115,586 | |
| |
| | | |
| | |
Cost of Sales | |
| 526,817 | | |
| 201,154 | |
Gross Profit (Loss) | |
| 390,345 | | |
| (85,568 | ) |
| |
| | | |
| | |
Operating Expenses: | |
| | | |
| | |
| |
| | | |
| | |
Sales and Marketing | |
| 3,410,277 | | |
| 1,347,585 | |
Research and Development | |
| 690,577 | | |
| 474,881 | |
General and Administrative | |
| 5,022,943 | | |
| 3,148,494 | |
| |
| | | |
| | |
Total Operating Expenses | |
| 9,123,797 | | |
| 4,970,960 | |
| |
| | | |
| | |
Operating Loss | |
| (8,733,452 | ) | |
| (5,056,528 | ) |
| |
| | | |
| | |
Other Income | |
| | | |
| | |
Forgiveness of PPP Loan and Accrued Interest | |
| - | | |
| 31,680 | |
Interest Income | |
| 15,844 | | |
| 9,853 | |
Total Other Income | |
| 15,844 | | |
| 41,533 | |
| |
| | | |
| | |
Net Loss before taxes | |
| (8,717,608 | ) | |
| (5,014,995 | ) |
| |
| | | |
| | |
Income Tax Provision | |
| - | | |
| - | |
| |
| | | |
| | |
Net Loss | |
$ | (8,717,608 | ) | |
$ | (5,014,995 | ) |
| |
| | | |
| | |
Net Loss Per Share: | |
| | | |
| | |
Basic and Diluted | |
$ | (0.85 | ) | |
$ | (0.57 | ) |
| |
| | | |
| | |
Weighted Average Common Shares Outstanding: | |
| | | |
| | |
Basic and Diluted | |
| 10,222,994 | | |
| 8,760,877 | |
PETVIVO
HOLDINGS, INC.
CONSOLIDATED
BALANCE SHEETS
| |
March 31, 2023 | | |
March 31, 2022 | |
Assets: | |
| | | |
| | |
Current Assets | |
| | | |
| | |
Cash and cash equivalents | |
$ | 475,314 | | |
$ | 6,106,827 | |
Accounts receivable | |
| 86,689 | | |
| 2,596 | |
Inventory, net | |
| 370,283 | | |
| 98,313 | |
Prepaid expenses and other current assets | |
| 491,694 | | |
| 547,664 | |
Total Current Assets | |
| 1,423,980 | | |
| 6,755,400 | |
| |
| | | |
| | |
Property and Equipment, net | |
| 630,852 | | |
| 311,549 | |
| |
| | | |
| | |
Other Assets: | |
| | | |
| | |
Operating lease right-of-use | |
| 317,981 | | |
| 299,101 | |
Patents and trademarks, net | |
| 38,649 | | |
| 48,452 | |
Security deposit | |
| 27,490 | | |
| 12,830 | |
Total Other Assets | |
| 384,120 | | |
| 360,383 | |
Total Assets | |
$ | 2,438,952 | | |
$ | 7,427,332 | |
| |
| | | |
| | |
Liabilities and Stockholders’ Equity: | |
| | | |
| | |
| |
| | | |
| | |
Current Liabilities | |
| | | |
| | |
Accounts payable | |
$ | 588,713 | | |
$ | 323,384 | |
Accrued expenses | |
| 779,882 | | |
| 784,375 | |
Operating lease liability – short term | |
| 78,149 | | |
| 59,178 | |
Note payable and accrued interest | |
| 6,936 | | |
| 6,549 | |
Total Current Liabilities | |
| 1,453,680 | | |
| 1,173,486 | |
Other Liabilities | |
| | | |
| | |
Note payable and accrued interest (net of current portion) | |
| 20,415 | | |
| 27,201 | |
Operating lease liability (net of current portion) | |
| 239,832 | | |
| 239,923 | |
Total Other Liabilities | |
| 260,247 | | |
| 267,124 | |
Total Liabilities | |
| 1,713,927 | | |
| 1,440,610 | |
| |
| | | |
| | |
Commitments and Contingencies | |
| | | |
| | |
| |
| | | |
| | |
Stockholders’ Equity: | |
| | | |
| | |
Preferred stock, par value $0.001, 20,000,000 shares authorized, no shares issued and outstanding at March 31, 2023 and March 31, 2022 | |
| - | | |
| - | |
Common stock, par value $0.001, 250,000,000 shares authorized, 10,950,220 and 9,988,361 shares issued and outstanding at March 31, 2023 and March 31, 2022, respectively | |
| 10,950 | | |
| 9,988 | |
Common Stock to be Issued | |
| 137,500 | | |
| - | |
Additional Paid-In Capital | |
| 72,420,604 | | |
| 69,103,155 | |
Accumulated Deficit | |
| (71,844,029 | ) | |
| (63,126,421 | ) |
Total Stockholders’ Equity | |
| 725,025 | | |
| 5,986,722 | |
Total Liabilities and Stockholders’ Equity | |
$ | 2,438,952 | | |
$ | 7,427,332 | |
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=PETV_WarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jun 2024 to Jul 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jul 2023 to Jul 2024